Drug intelligence / Profile preview

ABOR2014

Development stage: Phase 1
Lead developer: ePOCT Biotech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ABOR2014 (also known as IPM511) is a personalized mRNA-based neoantigen cancer vaccine developed by ePOCT Biotech. It is designed to encode tumor-specific neoantigens unique to an individual patient's tumor, aiming to stimulate a robust T-cell-mediated immune response against cancer cells. The vaccine is administered via intramuscular injection and has been primarily investigated for the treatment of advanced hepatocellular carcinoma (HCC) and colorectal cancer. Clinical evaluation included an investigator-initiated trial at Peking Union Medical College Hospital (NCT05981066/ChiCTR2300073495). Current reports indicate that the development of this asset has been discontinued.

Other names: ABOR2014ABOR-2014ABOR 2014IPM511IPM-511IPM 511

Beyond the preview

Go deeper on ABOR2014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABOR2014.

Explore the full profile